



Please find our Research on Bloomberg BRYG <GO>

1st September 2016

## BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
<b>Indices</b>			
Dow Jones	18400.88	-0.29%	+5.60%
S&P 500	2170.95	-0.24%	+6.21%
Nasdaq	5213.22	-0.19%	+4.11%
Nikkei	16926.84	+0.23%	-11.28%
Stoxx 600	343.532	-0.35%	-6.09%
CAC 40	4438.22	-0.43%	-4.29%
<b>Oil /Gold</b>			
Crude WTI	44.7	-3.56%	+20.16%
Gold (once)	1307.93	-0.77%	+23.11%
<b>Currencies/Rates</b>			
EUR/USD	1.11375	-0.13%	+2.53%
EUR/CHF	1.09435	-0.04%	+0.64%
German 10 years	-0.127	-19.25%	-119.95%
French 10 years	0.162	+9.96%	-83.47%

### Economic releases :

Date	
1st-Sept	CNY - Manuf PMI Aug. (50.4A, 49.9E, 49.9P) CNY - Non Manuf PMI Aug. (53.5A, 53.9P) FR - PMI Manuf Index DE - PMI Manuf Index US - Initial Jobless Claims US - DOE Oil Inventories

### Upcoming BG events :

Date	
1st-Sept	L'OREAL (BG Paris roadshow with CFO)
8th-Sept	ACCOR (BG Roadshow with CFO)
13th-Sept	Thematic Breakfast with ARCEP
14th-Sept	SAINT GOBAIN (BG Luxembourg roadshow)
22nd-Sept	Thematic Lunch with HC specialist
30th-Sept	Thematic Breakfast with Vimpelcom

### Recent reports :

Date	
24th-Aug	AMS Catching the ball when it bounces - all a question of timing
26th-Jul	NICOX Don't turn a blind eye to opportunities
21st-Jul	SEMICONDUCTORS : Looking for lost growth
13th-Jul	Oncology is an increased focus
12th-Jul	DANONE No redemption
1st-Jul	UBISOFT Same player shoot again?

List of our Reco & Fair Value : Please click here to download



### BIOMÉRIEUX

NEUTRAL, Fair Value EUR130 (-5%)

*"At or above" already priced in, backing profit-taking moves*

BIM's Q2 conference call focused on new guidance and profitability levels, both for FilmArray and at the group level. Sales guidance seems conservative in our view (BGE 9.4% CER growth for the year vs guidance "at or above 8% CER"). Despite FilmArray now being accretive to the group's EBIT margin, we do not see the latter progressing to the same extent as sales over the year (i.e. significantly above communicated guidance, BGE EUR291m vs guidance EUR265-290m). NEUTRAL rating reiterated but Fair Value increased however from EUR127 to EUR130.

### EIFFAGE

BUY, Fair Value EUR77 vs. EUR73 (+10%)

*Nice interim figures, decent outlook : difficult to be disappointed.*

Difficult to be disappointed by the fine earnings at end-June, combined with confident comments from management on the group's outlook. H1 2016 current EBIT rose to EUR677m (3.5% above consensus\*) representing a 10.4% margin, up 140bps y/y, with improvement in almost all businesses. The order book was solid, up 1.6% at more than EUR12bn. Guidance is positive, with margin improvement expected in most divisions, while the decline in financial charges should be higher than initially guided. Still a Buy.

### PERNOD RICARD

NEUTRAL, Fair Value EUR107 (+4%)

*2015/16 results: first take*

Q4 organic sales fell 0.7%, below consensus (+0.7%) but globally in line with our estimate (-1%). This weak performance was due to tough comps in France and the reversal of shipment loading in the US in Q3. Full year EBIT rose 2.1% organically (consensus: +1.9% and our estimate: +1.7%), in the mid range of the guidance (+1/3%). Guidance for 2016/17 is for organic EBIT growth between 2% and 4%.

### RÉMY COINTREAU

BUY, Fair Value EUR80 (+2%)

*Some newsflows*

Rémy Cointreau has launched a private placement of bonds convertible into new shares and/or exchangeable for existing shares due in 2026 for an amount of EUR275m. It has also entered into exclusive negotiations with Luca Bols to create a joint venture for the Passoa brand (passion fruit liqueur).

### SOFTWARE AG

BUY, Fair Value EUR40 (+12%)

*Announcing the Adabas & Natural 2050 agenda and acquisition of ConnX Solutions*

Yesterday Software AG made its Adabas & Natural (A&N) 2050 roadmap official, launching an extended services portfolio and the integration of Mobile, Big Data and DevOps capabilities. It also announced the acquisition of ConnX Solutions, a software vendor specialised in data integration and replication, which has been a partner in A&N for over 10 years. While the contribution of both is difficult to quantify, we consider these two moves will help Software AG soften the decline in the A&N business (est. 27% of sales and a 68% margin) over the medium-term.

### In brief...

BUREAU VERITAS, *New opportunist bond issue*

ROCHE, *Positive Phase III study for Tecentriq in NSCLC*

Healthcare

**bioMérieux**

Price EUR136.35

**"At or above" already priced in, backing profit-taking moves**

Fair Value EUR130 (-5%)

**NEUTRAL**

Bloomberg	BIM FP
Reuters	BIOX.PA
12-month High / Low (EUR)	136.4 / 93.7
Market Cap (EUR)	5,380
Ev (BG Estimates) (EUR)	5,779
Avg. 6m daily volume (000)	41.60
3y EPS CAGR	29.6%

**BIM's Q2 conference call focused on new guidance and profitability levels, both for FilmArray and at the group level. Sales guidance seems conservative in our view (BGe 9.4% CER growth for the year vs guidance "at or above 8% CER"). Despite FilmArray now being accretive to the group's EBIT margin, we do not see the latter progressing to the same extent as sales over the year (i.e. significantly above communicated guidance, BGe EUR291m vs guidance EUR265-290m). NEUTRAL rating reiterated but Fair Value increased however from EUR127 to EUR130.**

**ANALYSIS**

- BIM's refined sales guidance (at or above the high range of 6-8% CER vs. 6-8% CER) implies a 5%-6% CER growth in H2 2016, which compares with a strong 10.9% CER in H1 2016. Although translating improving trends across the board, driven by FilmArray, this adjustment is not a significant shift as we would have expected for a +/-150bp upgrade. Indeed, it carries numerous unknowns, clouding the visibility we had in H1 2016 which might impact performance in the second half of 2016. **1)** some Western European countries such as France and Italy, which together represent more than 10% of sales, are under continuous pressure. Note that EMEA grew 2.1% CER in H1 (42% of sales). **2)** volatility around APAC performance, notably in China which represents 8% to 10% of sales. **3)** Roche's PCT test was approved in July in the US and is a direct competitor to VIDAS BRAHMS PCT test (6% of sales).

In light of this, we prefer to be somewhat reassuring and would point out that **1)** during previous conference calls, management mentioned that the shift in the French lab market to become more automated was being addressed, **2)** APAC performance, driven by reagent sales, was an early sign of stabilisation in the region and **3)** that long-term contracts in the US are in place for VIDAS BRAHMS.

Hence, we believe that despite management's refined sales guidance (increased from 6%-8% CER growth to "at or above the high end of the 6-8% CER range"), the FY2016 CER sales growth rate could stand +/- 150bp above 8% CER growth rate (BGe 9.4% CER). Although it is too early to be integrated into our estimates, it is worth noting that a low/mid-flu season is factored into guidance, which could represent further upside potential for BIM if the flu season proves to be of higher intensity (~80% of FilmArray sales relies on the respiratory panel).

- Turning to profitability, we welcome management's indication on profitability levels for FilmArray, which is accretive to both gross and EBIT margin i.e. above group level. This is a clear positive as it is fair to think that FilmArray could reach a ~25% EBIT margin towards 2020e, representing 22% of the group's contributive EBIT margin (vs. 12% in 2016e, BGe). Alongside an improving gross margin in H1 2016, this favours an adjustment in the company's contributive EBIT margin guidance to the high end of the previously communicated EUR265-290m range. Our old numbers were already pretty much aligned with this new guidance so are the new ones (BGe EUR291m vs EUR284m). **1)** increased commercial costs should weigh on margins in H2 as they will be booked over the full semester (vs. 1/2 in H1), and **2)** higher instrument sales expected in H2 (integrated by CSS already) should not give the group the opportunity to increase its EBIT to the same extent as sales. Note that the new facility for FilmArray should not have a positive impact in 2016.

**VALUATION**

- While sales guidance seems conservative in our view (BGe 9.4% CER growth for the year), we do not see the contributive EBIT margin progressing to the same extent (i.e. significantly above communicated guidance). We reiterate our NEUTRAL rating but increase however our Fair Value from EUR127 to EUR130. Despite BIM offering a safe heaven compared to other segments in the HC industry, we consider the share is fully valued and would take some profits at these levels.

**NEXT CATALYSTS**

- 20th October: Q3 sales

[Click here to download](#)

	1 M	3 M	6 M	31/12/15
Absolute perf.	10.3%	16.2%	16.3%	24.1%
Healthcare	-5.6%	-2.6%	2.0%	-8.5%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	1,965	2,096	2,259	2,420
% change		6.7%	7.8%	7.1%
EBITDA	380	427	469	545
EBIT	260.0	290.3	321.9	387.2
% change		11.7%	10.9%	20.3%
Net income	110.3	164.3	194.4	239.9
% change		49.0%	18.3%	23.4%

	2015	2016e	2017e	2018e
Operating margin	13.2	13.9	14.3	16.0
Net margin	5.6	7.8	8.6	9.9
ROE	7.3	10.1	11.0	12.3
ROCE	8.2	8.5	9.2	10.8
Gearing	14.9	24.6	19.0	10.8

(EUR)	2015	2016e	2017e	2018e
EPS	2.80	4.16	4.93	6.08
% change	-	49.0%	18.3%	23.4%
P/E	48.8x	32.7x	27.7x	22.4x
FCF yield (%)	1.3%	NM	2.3%	3.7%
Dividends (EUR)	1.00	1.04	1.23	1.52
Div yield (%)	0.7%	0.8%	0.9%	1.1%
EV/Sales	2.9x	2.8x	2.5x	2.3x
EV/EBITDA	14.7x	13.5x	12.2x	10.3x
EV/EBIT	21.6x	19.9x	17.8x	14.4x



**Analyst :**  
 Hugo Solvet  
 33(0) 1 56 68 75 57  
[hsolvet@bryangarnier.com](mailto:hsolvet@bryangarnier.com)

**Sector Team :**  
 Mickael Chane Du  
 Eric Le Berrigaud

Construction & Building Materials

**Eiffage**

Price EUR70.20

Nice interim figures, decent outlook : difficult to be disappointed.

Fair Value EUR77 vs. EUR73 (+10%)

BUY

Bloomberg	FGR FP
Reuters	FOUG.PA
12-month High / Low (EUR)	71.2 / 54.3
Market Cap (EUR)	6,885
Ev (BG Estimates) (EUR)	21,176
Avg. 6m daily volume (000)	352.5
3y EPS CAGR	18.4%

Difficult to be disappointed by the fine earnings at end-June, combined with confident comments from management on the group's outlook. H1 2016 current EBIT rose to EUR677m (3.5% above consensus\*) representing a 10.4% margin, up 140bps y/y, with improvement in almost all businesses. The order book was solid, up 1.6% at more than EUR12bn. Guidance is positive, with margin improvement expected in most divisions, while the decline in financial charges should be higher than initially guided. Still a Buy.

H1 2016 performance

EURm	Sales	y/y %	EBIT	EBIT mrg	Abps
Constr. ex-property development	1400	4.1	40	2.9	11
Property development	329	7.7	24	7.3	42
Infra	1925	-3.8	-40	-2.1	7
Energy	1623	-9.5	49	3.0	23
APRR	1116	5.6	537	48.1	396
Others concessions/PPP	104	1.9	79	75.9	-94
<b>Revenues</b>	<b>6497</b>	<b>-1.6</b>	<b>677</b>	<b>10.4</b>	<b>140</b>

Source : Company Data; Bryan Garnier & Co. ests.

\*Consensus figures from Financial Inquiry

	1 M	3 M	6 M	31/12/15
Absolute perf.	2.1%	5.9%	7.5%	17.9%
Cons & Mat	4.2%	3.5%	10.6%	5.2%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	13,909	13,810	14,066	14,341
% change		-0.7%	1.8%	2.0%
EBITDA	2,074	2,132	2,209	2,326
EBIT	1,431	1,547	1,619	1,731
% change		8.1%	4.7%	6.9%
Net income	312.0	399.2	444.9	541.5
% change		27.9%	11.4%	21.7%

	2015	2016e	2017e	2018e
Operating margin	10.3	11.2	11.5	12.1
Net margin	3.3	4.2	4.6	5.5
ROE	13.2	14.5	14.4	15.3
ROCE	5.1	5.4	5.7	6.2
Gearing	351.2	292.5	251.7	209.3

(EUR)	2015	2016e	2017e	2018e
EPS	3.37	4.16	4.64	5.59
% change	-	23.5%	11.5%	20.5%
P/E	20.8x	16.9x	15.1x	12.6x
FCF yield (%)	7.4%	6.2%	7.7%	10.5%
Dividends (EUR)	1.50	1.50	1.50	1.50
Div yield (%)	2.1%	2.1%	2.1%	2.1%
EV/Sales	1.5x	1.5x	1.5x	1.4x
EV/EBITDA	10.4x	9.9x	9.4x	8.7x
EV/EBIT	15.0x	13.7x	12.9x	11.7x

ANALYSIS

- H1 2016 revenues were down 2% lfl at EUR6497m. The decline was mostly due to a poor comparison basis, with the high-speed rail line BPL contribution (infrastructure division) down cEUR120m Y/Y, since the project is almost completed. Besides, Eiffage Energy benefited last year from EUR170m in revenues from the Cestas solar plant. Otherwise, sales would have been slightly up by approx. 3% according to our calculation. **Outlook is fine:** management reiterated its guidance for a "slight decline in activity" in 2016 but the order book is fine, up 1.6% (4.7% excluding BPL), which means 2017 should definitely be a year of top-line growth in our view. In addition, Eiffage mentioned the "ongoing stabilisation of volumes" in the French roadworks business, while construction is doing good, especially property development (reservations up 14%). Summer APRR traffic trends are similar than H1 volumes (adjusted from various non-recurrent effects though).
- Current operating margins improved in almost every business in H1. Infrastructure profitability was flat though, as the metal and roadworks environments were still difficult in France in H1, while APRR benefited from EUR35m less depreciation. **Outlook is positive:** Construction, Energy and Infrastructure should report better operating margins for the full year, to the same extent as H1 for the first two divisions. Infrastructure should benefit from the improvement in profitability in Metal (positive contribution expected vs breakeven previously). We have upgraded our current EBIT estimates by approx. 3% in 2016.
- The decline in financial charges was impressive in H1 (-EUR67m) but most of it stemmed from APRR/Eiffage. As the refinancing started in H2 last year, Eiffage has made only minor changes to its FY guidance with a EUR60m fall in financial charges expected versus EUR50m previously. We have upgraded our EPS estimates by approx. 4% for 2016 with a fairly similar impact on our valuation.

VALUATION

- EUR77 vs EUR73 FV derived from an updated SOTP, based on our new forecasts.

NEXT CATALYSTS

- Q3 sales of APRR on 20 October 2016; Q3 sales of Eiffage on 7th November 2016.

[Click here to download](#)



Analyst :  
Eric Lemarié  
33(0) 1.70.36.57.17  
elemarie@bryangarnier.com

Food & Beverages

**Pernod Ricard**

Price EUR102.90

2015/16 results: first take

Fair Value EUR107 (+4%)

NEUTRAL

Q4 organic sales fell 0.7%, below consensus (+0.7%) but globally in line with our estimate (-1%). This weak performance was due to tough comps in France and the reversal of shipment loading in the US in Q3. Full year EBIT rose 2.1% organically (consensus: +1.9% and our estimate: +1.7%), in the mid range of the guidance (+1/3%). Guidance for 2016/17 is for organic EBIT growth between 2% and 4%.

Bloomberg	RI FP
Reuters	PERP.PA
12-month High / Low (EUR)	108.9 / 88.3
Market Cap (EUR)	27,312
Ev (BG Estimates) (EUR)	35,866
Avg. 6m daily volume (000)	493.5
3y EPS CAGR	2.8%

ANALYSIS

Full year net sales amounted to EUR8,682m (consensus: EUR8,770m and our estimate: EUR8,693m), up 1.4% on a reported basis and 1.8% organically (CS: +2.1% and our estimate: +1.7%). Q4 organic net sales dropped 0.7%, decelerating vs Q3 (+0.8%). Full year EBIT increased 1.7% to EUR2,277m (consensus: EUR2,280m and our estimate: EUR2,247m). Organic EBIT growth was 2.1%, in the mid range of the group's guidance (+1/3%), and slightly above expectations (consensus: +1.9% and our estimate: +1.7%). This was due to cost containment and improving pricing. The EBIT margin was stable at 26.2%. EPS was up 4% to 5.20EUR.

In **Asia-ROW** (42% of group's sales), Q4 organic net sales decreased 1.9% (consensus: +2% and our estimate: +1.5%) after -5.4% in Q3. This reflects a destocking in South East Asia, a challenging environment for the Travel Retail and a decline in China. The Chinese performance was roughly in line with what was indicated at the Q3 sales release (organic sales down 9% over the year). FY EBIT margin in Asia-ROW decreased 90bp to 28.1%, driven by negative geographical mix. In the **Americas** (28% of group's sales), net sales dropped 1.3% (consensus: -2% and our estimate: -4%) organically in Q4 (+11.1% in Q3) because of the reversal of shipment loading in Q3 in the US. FY EBIT margin in the region increased 200bp to 28.5% thanks to FX. **Europe** (30% of group's sales) posted a 1.1% increase in organic net sales last quarter (consensus: +1% and our estimate: -1%) after +1.6% in Q3. This was mainly due to the very tough comparison base in France where the group overshipped in Q4 2014/15 before the merger of Pernod's and Ricard's IT systems. FY EBIT margin dropped 50bps to 21.7% driven by FX.

Guidance for 2016/17 is for organic EBIT growth between 2% and 4% (consensus: +3.8%). The group also expects a, improvement of China and Absolut in the US. 2015/16 net debt amounted to EUR8,716m at end-June 2016, down EUR305m, mainly thanks to improved free cash flow (+4% in reported and on a recurring basis. The reported net debt/EBITDA ratio improved from 3.6x to 3.4x. A dividend of EUR1.88 (+4% vs last year) is to be proposed in respect of 2015/16, in line with the customary payout policy of approximately 1/3rd of net profit from recurring operations.

VALUATION

Our DCF points to a Fair Value of EUR106.

NEXT CATALYSTS

The group will hold its shareholders' meeting on 17<sup>th</sup> November

[Click here to download](#)

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.7%	5.1%	4.9%	-2.2%
Food & Bev.	-1.4%	1.5%	4.9%	0.0%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

YEnd Jun. (EURm)	06/15	06/16e	06/17e	06/18e
Sales	8,558	8,693	8,797	9,089
% change		1.6%	1.2%	3.3%
EBITDA	2,456	2,595	2,583	2,663
EBIT	2,238	2,247	2,249	2,336
% change		0.4%	0.1%	3.9%
Net income	1,329	1,343	1,365	1,443
% change		1.0%	1.6%	5.7%

	06/15	06/16e	06/17e	06/18e
Operating margin	26.2	25.8	25.6	25.7
Net margin	10.1	14.7	14.8	15.2
ROE	6.6	9.1	9.0	9.1
ROCE	8.8	10.9	10.7	10.9
Gearing	67.9	60.0	55.1	50.0

(EUR)	06/15	06/16e	06/17e	06/18e
EPS	4.99	5.04	5.13	5.42
% change	-	1.1%	1.6%	5.7%
P/E	20.6x	20.4x	20.1x	19.0x
FCF yield (%)	4.2%	4.2%	4.1%	4.3%
Dividends (EUR)	1.80	1.83	1.86	1.97
Div yield (%)	1.7%	1.8%	1.8%	1.9%
EV/Sales	4.2x	4.1x	4.0x	3.9x
EV/EBITDA	14.8x	13.8x	13.7x	13.2x
EV/EBIT	16.2x	16.0x	15.7x	15.0x



Analyst :  
 Virginie Roumage  
 33(0) 1.56.68.75.22  
 vroumage@bryangarnier.com

Sector Team :  
 Nikolaas Faes  
 Loïc Morvan  
 Antoine Parison  
 Cédric Rossi

Food & Beverages

**Rémy Cointreau**

Price EUR78.23

Some newsflows

Fair Value EUR80 (+2%)

BUY

Rémy Cointreau has launched a private placement of bonds convertible into new shares and/or exchangeable for existing shares due in 2026 for an amount of EUR275m. It has also entered into exclusive negotiations with Luca Bols to create a joint venture for the Passoã brand (passion fruit liqueur).

ANALYSIS

- Rémy Cointreau has launched a private placement of bonds convertible into new shares and/or exchangeable for existing shares due in 2026 for an amount of EUR275m. This aims at 1/ refinancing EUR205m in bonds maturing in December 2016 and with a coupon of 5.18%, and 2/ serving the general financing purposes of the company. The conversion ratio is one share per OCEANE and the issue premium is 40%. The OCEANEs may be redeemed early at the option of the company from September 2021 if the average share price exceeds 130% of the nominal value of the OCEANEs (EUR110.70). They enable Rémy Cointreau to benefit from very low interest rates (0.125%). As a reminder, the group does not have investment grade rating (BB+). The decrease in finance costs would increase our net result estimate by 6%. But the impact on our EPS forecast would be roughly neutral (+0.5%) due to the increase in the number of diluted shares (+2 484 191)
- The group has also entered into exclusive negotiations with Luca Bols to create a joint venture, for the Passoã brand (passion fruit liqueur). Under the proposed agreement, Rémy Cointreau would contribute all Passoã operations, including trademarks and inventory, while Lucas Bols would contribute both its know-how and expertise in the liqueur and cocktail business, as well as working capital. Lucas Bols would assume operational and financial control of the joint venture. This project forms part of Rémy Cointreau's strategy to premiumise its portfolio. It aims to generate 60-65% of its sales from exceptional spirits by 2019/20 (49% in 2015/16). The transaction is expected to close before the end of 2016.

VALUATION

- We maintain unchanged our estimates pending discussions with the company. Our DCF currently points to a Fair Value of EUR80.

NEXT CATALYSTS

- The group will release its Q2 sales on 18th October

[Click here to download](#)

Bloomberg	RCO FP
Reuters	RCOP.PA
12-month High / Low (EUR)	80.4 / 50.9
Market Cap (EURm)	3,813
Ev (BG Estimates) (EURm)	4,257
Avg. 6m daily volume (000)	90.20
3y EPS CAGR	13.2%

	1 M	3 M	6 M	31/12/15
Absolute perf.	0.0%	4.8%	22.8%	18.5%
Food & Bev.	-1.4%	1.5%	4.9%	0.0%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

YEnd Mar. (EURm)	03/16	03/17e	03/18e	03/19e
Sales	1,051	1,069	1,133	1,214
% change		1.7%	6.1%	7.1%
EBITDA	200	220	244	270
EBIT	178.4	199.3	221.0	244.9
% change		11.7%	10.9%	10.8%
Net income	110.4	124.5	142.8	160.0
% change		12.8%	14.7%	12.1%

	03/16	03/17e	03/18e	03/19e
Operating margin	17.0	18.7	19.5	20.2
Net margin	10.5	11.6	12.6	13.2
ROE	9.9	11.5	13.5	14.6
ROCE	16.5	17.3	18.0	18.3
Gearing	41.2	41.1	38.1	31.6

(EUR)	03/16	03/17e	03/18e	03/19e
EPS	2.27	2.56	2.93	3.29
% change	-	12.8%	14.7%	12.1%
P/E	34.5x	30.6x	26.7x	23.8x
FCF yield (%)	2.0%	2.7%	3.1%	3.5%
Dividends (EUR)	1.60	1.60	1.60	1.60
Div yield (%)	2.0%	2.0%	2.0%	2.0%
EV/Sales	4.1x	4.0x	3.7x	3.4x
EV/EBITDA	21.4x	19.4x	17.3x	15.4x
EV/EBIT	23.9x	21.4x	19.1x	17.0x



Analyst :  
 Virginie Roumage  
 33(0) 1.56.68.75.22  
 vroumage@bryangarnier.com

Sector Team :  
 Nikolaas Faes  
 Loïc Morvan  
 Antoine Parison  
 Cédric Rossi

TMT

**Software AG**

Price EUR35.62

**Announcing the Adabas & Natural 2050 agenda and acquisition of Connx Solutions**

Fair Value EUR40 (+12%)

BUY

Bloomberg	SOW GR
Reuters	SOWG.DE
12-month High / Low (EUR)	36.7 / 23.8
Market Cap (EURm)	2,814
Ev (BG Estimates) (EURm)	2,682
Avg. 6m daily volume (000)	201.8
3y EPS CAGR	5.2%

Yesterday Software AG made its Adabas & Natural (A&N) 2050 roadmap official, launching an extended services portfolio and the integration of Mobile, Big Data and DevOps capabilities. It also announced the acquisition of Connx Solutions, a software vendor specialised in data integration and replication, which has been a partner in A&N for over 10 years. While the contribution of both is difficult to quantify, we consider these two moves will help Software AG soften the decline in the A&N business (est. 27% of sales and a 68% margin) over the medium-term.

	1 M	3 M	6 M	31/12/15
Absolute perf.	-1.2%	2.1%	9.4%	34.8%
Softw. & Comp.	1.0%	5.5%	11.4%	5.3%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

**ANALYSIS**

- Announcing the Adabas & Natural roadmap.** Software AG yesterday released details of its agenda to support and further develop its Adabas & Natural product portfolio until beyond 2050. In order to leverage its digitisation capabilities to Adabas & Natural enterprise applications, Software AG is launching an extended services portfolio named "A&N Managed Services", which provides staff training, and application modernisation, management and operations to protect the investments made by customers and extend the life-cycle of their mission-critical applications. New A&N product releases and capabilities, as underlined in a recent statement of direction for 2015-2020, include: 1) Mobile, by adding capabilities to develop mobile-optimised applications with Natural; 2) Big Data, by replicating Adabas data in real-time into Terracotta In-memory to enable internet scale applications and services, and through the integration with Apama Streaming Analytics to develop analytic solutions with real-time insights and decisions; 3) DevOps, by extending capabilities to improve DevOps tasks in the Eclipse-based NaturalOne (support, profiling, testing).

YEnd Dec. (€m)	2015	2016e	2017e	2018e
Sales	873.1	889.8	922.4	964.7
% change		1.9%	3.7%	4.6%
EBITDA	278	291	307	328
EBIT	209.4	239.1	261.5	283.2
% change		14.2%	9.3%	8.3%
Net income	188.0	192.7	203.7	218.9
% change		2.5%	5.7%	7.5%

- Acquisition of Connx Solutions.** Founded in 1989 and based in Redmond (USA), Connx Solutions provides API-based data integration/replication technology for Adabas & Natural customers. The company has been an OEM partner of Software AG for over 10 years with broad adoption within the Adabas & Natural customer base. The rationale of the acquisition for Software AG is to secure access to this technology in the light of the 2050 agenda. In addition, Software AG customers gain access to the full range of Connx Solutions technologies (SQL data access, ETL, data sync, desktop query and reporting, cloud integration, integration with Excel...). The acquisition closed on 31st July. We have no details regarding the acquisition price and the revenues Connx generates, but at first glance we doubt the company will have a significant contribution to Software AG's P&L.

	2015	2016e	2017e	2018e
Operating margin	30.2	31.0	31.7	32.5
Net margin	16.0	17.7	19.0	19.8
ROE	12.8	13.1	13.1	13.0
ROCE	17.7	18.5	20.0	22.0
Gearing	1.3	-11.0	-22.0	-31.7

- Efforts to soften the decline in A&N revenues.** We estimate that Adabas & Natural products, before the contribution of Connx Solutions, will account for 27% of revenues to EUR240m (-3% vs. 2015) vs. company guidance of -6%/-2% at cc) with a margin of 68% (70% in 2015) before G&A and central costs. For H1 2016, the A&N division was up 7% lfl with +20% lfl in Q1 especially on the back of a large deal which was booked ahead of schedule. While the impact of the roadmap and Connx are challenging to evaluate, we expect A&N revenues to fall 6-7% lfl by 2019-2020, but we cannot rule out the prospect of this decline being softened in the medium-term by a sustained software renewal rate (currently 98%) and Connx products. In addition, the addition of A&N Managed Services could enhance services revenue growth (est. +4.5% for 2020).

(€)	2015	2016e	2017e	2018e
EPS	2.33	2.39	2.53	2.71
% change	-	2.5%	5.8%	7.5%
P/E	15.3x	14.9x	14.1x	13.1x
FCF yield (%)	6.1%	6.8%	7.4%	8.0%
Dividends (€)	0.55	0.60	0.65	0.70
Div yield (%)	1.5%	1.7%	1.8%	2.0%
EV/Sales	3.2x	3.0x	2.7x	2.4x
EV/EBITDA	10.2x	9.2x	8.2x	7.2x
EV/EBIT	10.7x	9.7x	8.6x	7.5x

**VALUATION**

- Software AG's shares are trading at est. 9.7x 2016 and 8.6x 2017 EV/EBIT multiples.
- Net cash position on 30th June 2016 was EUR65.8m (net gearing: -6%).

**NEXT CATALYSTS**

Q3 2016 results on 20th October before markets open.

[Click here to download](#)



**Analyst :**  
 Gregory Ramirez  
 33(0) 1 56 68 75 91  
[gramirez@bryangarnier.com](mailto:gramirez@bryangarnier.com)

**Sector Team :**  
 Richard-Maxime Beaudoux  
 Thomas Coudry  
 Dorian Terral

Business Services

**Bureau Veritas**

Price EUR19.22

**New opportunist bond issue**

Fair Value EUR21 (+9%)

**NEUTRAL**

Bloomberg	BVI.FP
Reuters	BVI.PA
12-month High / Low (EUR)	21.0 / 16.1
Market Cap (EURm)	8,495
Avg. 6m daily volume (000)	676.7

	1 M	3 M	6 M	31/12/15
Absolute perf.	-1.1%	-0.5%	4.6%	4.5%
Incls Gds & Svs	2.8%	2.1%	9.6%	3.6%
DJ Stoxx 600	0.5%	-1.1%	2.9%	-6.1%

	2015	2016e	2017e	2018e
P/E	20.0x	19.7x	18.8x	17.5x
Div yield (%)	2.7%	2.7%	2.8%	3.0%

**ANALYSIS**

- In view of beneficial financial market conditions and strong demand, BVI has launched a new bond issue for a total amount of EUR700m. The issue is split between two components i.e. EUR500m with a 7-year maturity with a coupon of 1.25% and EUR200m with a 10-year maturity and a coupon of 2%. Note that the issue was respectively oversubscribed 8 times and 2.5 times.
- First of all, the new issue will refinance the EUR500m bond maturing in May 2017 with a coupon of 3.75% and will lengthen and increase group resources to pursue its M&A strategy.
- At the end of June, BVI's adjusted net debt reached EUR2,184m (gross debt of EUR2,391) vs. EUR1,863m (gross debt of EUR2,390m) at the end of December 2015, representing financial leverage of 2.4x and 2x respectively for a covenant of 3.25x. The average cost of debt was 3.5% at the end of 2015 (3.7% at the end of 2014). In all, taking into account that issue and after May 2017, the cost of debt will be reduced by EUR8m compared with net finance costs of EUR89m in 2015.

**VALUATION**

- At the current share price, the stock is trading on 2016e and 2017e EV/EBIT multiples of 13.7x and 13x respectively, compared with an historical median of 14.3x and CAGR in 2015-2018 EBIT of less than 3%.

**NEXT CATALYSTS**

- Q3 trading update on 7th November

[Click here to download](#)

Bruno de La Rochebrochard, [bdelarochebrochard@bryangarnier.com](mailto:bdelarochebrochard@bryangarnier.com)

Healthcare

**Roche**

Price CHF239.80

**Positive Phase III study for Tecentriq in NSCLC**

Fair Value CHF293 (+22%)

**BUY**

Bloomberg	ROG.VX
Reuters	ROG.VX
12-month High / Low (CHF)	279.3 / 233.2
Market Cap (CHFm)	168,475
Avg. 6m daily volume (000)	1,298

**ANALYSIS**

- Roche announces that OAK, a Phase III evaluating Tecentriq (atezolizumab, anti-PD-L1) as a monotherapy in patients 1) with advanced non-small cell lung cancer (NSCLC), 2) whose disease progressed on/after treatment with platinum-based chemo, met its co-primary endpoints (i.e. improvement in overall survival and progression-free survival).
- Obviously, this is good news but we assume this was widely expected given the track-record of the therapeutic class in this very indication. We got no details regarding the degree of improvement, be it in all-comers or depending on the level of expression of PD-L, but let's keep in mind that 1) BMS' Opdivo (nivolumab) improved the median OS by respectively +2.8 and +3.0 months vs docetaxel (HR: 0.73 and 0.59) in non-squamous and squamous platinum-refractory NSCLC; 2) in the POPLAR Phase II study, atezolizumab yielded very similar data in the 2L setting of NSCLC (median OS: 12.6 vs 9.7 months, HR: 0.73).

**VALUATION**

- BUY reiterated with a FV of CHF293. Now that we know that 1) GOYA unfortunately missed its primary endpoint (see our comment [here](#)), and 2) OAK is positive, all eyes will be on APHINITY which is in our view the most significant cancer-related catalyst (please see our feedback from the BG Oncology Day [here](#) for further details).

**NEXT CATALYSTS**

- 7-11 October: Data presentation from the GALLIUM study.
- 19<sup>th</sup> October: Potential approval of Tecentriq in 2L PD-L1+ NSCLC based on the BIRCH Phase II study.

[Click here to download](#)

Eric Le Berrigaud, [eleberrigaud@bryangarnier.com](mailto:eleberrigaud@bryangarnier.com)



## BG's Wake Up Call

# Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 55.3%

NEUTRAL ratings 33.3%

SELL ratings 11.3%

## Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
TMT	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Utilities	Xavier Caroen		33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
	Pierre-Antoine Chazal		33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Insurance	Olivier Pauchaut <i>(Head of Research)</i>		33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Hotels/Business Services	Bruno de La Rochebrochard		33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
Construction/ Infrastructures Building Materials	Eric Lemarié		33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing	Sophie Braincourt		33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager	Eric Monnier		33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at [www.bryangarnier.com](http://www.bryangarnier.com)

London	Paris	New York	Munich	New Delhi
Beaufort House 15 St. Botolph Street London EC3A 7BB Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559	26 Avenue des Champs Elysées 75008 Paris Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the Financial Conduct Authority (FCA) and the Autorité de Contrôle prudentiel et de résolution (ACPR)	750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member	Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062 +91 98 1111 5119 Fax +91 11 2621 9062 <b>Geneva</b> rue de Grenus 7 CP 2113 Genève 1, CH 1211 Tel +4122 731 3263 Fax+4122731 3243 <b>Regulated by the FINMA</b>



## BRYAN, GARNIER & Co

### Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

### Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

### Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

### Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

### Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

### Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....